AI-generated analysis. Always verify with the original filing.
Curis, Inc. announced financial results for the three- and twelve-month periods ended December 31, 2025, reporting Q4 net income of $19.4 million ($1.23 per share) versus a $9.6 million net loss in Q4 2024, and full-year net loss of $7.6 million ($0.58 per share) versus $43.4 million in 2024. Updates included clinical data from lymphoma and leukemia trials and a January 2026 PIPE financing with up to $80.8 million in gross proceeds.
Event Type
Disclosure
Mandatory
Variant
8-K
. Results of Operations and Financial Condition. On March 19, 2026, Curis, Inc. announced its financial results for the three- and twelve-month periods ended De
. Financial Statements and Exhibits. Exhibit Number Description 99.1 Press Release dated March 19 , 202 6 104 Cover Page Interactive Data File (embedded within
| Metric | Value | Basis |
|---|---|---|
| Revenues, net | $9.40 | GAAP |
| Net Loss | $-7.60 | GAAP |
| Net Loss per Share (Basic) | $-0.58 | GAAP |
| Research and Development Expenses | $28.30 | GAAP |
| General and Administrative Expenses | $14.00 | GAAP |